IX Biopharma logo

42C - IX Biopharma Share Price

S$0.28 -0.0  -1.8%

Last Trade - 10:04am

Sector
Healthcare
Size
Small Cap
Market Cap £103.1m
Enterprise Value £99.4m
Revenue £422k
Position in Universe 2790th / 5988
Bullish
Bearish
Unlock 42C Revenue
Momentum
Relative Strength (%)
1m +12.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -18.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1.29 7.45 5.80 6.38 0.25 0.67 -12.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2019, IX Biopharma Ltd revenues increased 41% to SP$294K. Net loss before extraordinary items decreased 17% to SP$5.8M. Revenues reflect Specialty Pharmaceutical segment increase from SP$50K to SP$161K. Lower net loss reflects Research and development decrease of 47% to SP$1.2M (expense), Others decrease of 84% to SP$168K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

42C Revenue Unlock 42C Revenue

Net Income

42C Net Income Unlock 42C Revenue

Normalised EPS

42C Normalised EPS Unlock 42C Revenue

PE Ratio Range

42C PE Ratio Range Unlock 42C Revenue

Dividend Yield Range

42C Dividend Yield Range Unlock 42C Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
42C EPS Forecasts Unlock 42C Revenue
Profile Summary

iX Biopharma Ltd. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of therapies for the treatment of acute and breakthrough pain, and male erectile dysfunction. Its segments include Specialty Pharmaceutical and Chemical Analysis segments. The Specialty Pharmaceutical segment is engaged in the development, manufacturing and sale of pharmaceutical products. The Chemical Analysis segment is engaged in the provision of laboratory testing services. Its products are Wafermine, which is a sublingual ketamine oral wafer that contains the non-opioid drug for the management of moderate to severe pain; Bnox, which is a sublingual buprenorphine oral wafer that is developed as a formulation for moderate to severe pain; PheoniX, which is used for the treatment of male erectile dysfunction; WaferRest, which is used for the alleviation of jet lag and improving sleep quality, and Wafernyl, which is used for breakthrough cancer pain.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Public Since July 22, 2015
No. of Shareholders: 576
No. of Employees: 56
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Singapore Exchange Securities Trading Ltd
Shares in Issue 648,894,390
Free Float (0.0%)
Eligible for
ISAs
SIPPs
42C Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 42C
Upcoming Events for 42C
Friday 16th October, 2020 Estimate
IX Biopharma Ltd Annual Shareholders Meeting
Frequently Asked Questions for IX Biopharma
What is the IX Biopharma share price?

As of 10:04am, shares in IX Biopharma are trading at S$0.28, giving the company a market capitalisation of £103.1m. This share price information is delayed by 15 minutes.

How has the IX Biopharma share price performed this year?

Shares in IX Biopharma are currently trading at S$0.28 and the price has moved by 9.62% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IX Biopharma price has moved by 6.84% over the past year.

What are the analyst and broker recommendations for IX Biopharma?

Of the analysts with advisory recommendations for IX Biopharma, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for IX Biopharma is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will IX Biopharma next release its financial results?

IX Biopharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the IX Biopharma dividend yield?

IX Biopharma does not currently pay a dividend.

Does IX Biopharma pay a dividend?

IX Biopharma does not currently pay a dividend.

When does IX Biopharma next pay dividends?

IX Biopharma does not currently pay a dividend.

How do I buy IX Biopharma shares?

To buy shares in IX Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of IX Biopharma?

Shares in IX Biopharma are currently trading at S$0.28, giving the company a market capitalisation of £103.1m.

Where are IX Biopharma shares listed? Where are IX Biopharma shares listed?

Here are the trading details for IX Biopharma:

Country of listing: Singapore
Exchange: SES
Ticker Symbol: 42C
What kind of share is IX Biopharma?

Based on an overall assessment of its quality, value and momentum, IX Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a IX Biopharma share price forecast 2020?

Shares in IX Biopharma are currently priced at S$0.28. At that level they are trading at 50.88% discount to the analyst consensus target price of 0.00.

How can I tell whether the IX Biopharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IX Biopharma. Over the past six months, the relative strength of its shares against the market has been 52.54%. At the current price of S$0.28, shares in IX Biopharma are trading at 28.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the IX Biopharma PE Ratio?

We were not able to find PE ratio data for IX Biopharma.

Who are the key directors of IX Biopharma?

IX Biopharma's management team is headed by:

Yip Hang Lee - CHM
Shing Tung Ho - NED
Weng Keong Low - NID
Kwee Yee Teo - NID
Wei Hsiung Lee - SEC
Shin Lin Wang - SEC
Paul Edward Rolan - OTH
Li Fong Lam - OTH
Iain Cook - OTH
Sien Lup Chew - CFO
Kanakan Krishnarajah - COO
Patrick Davies - LED
Who are the major shareholders of IX Biopharma?

Here are the top five shareholders of IX Biopharma based on the size of their shareholding:

Lee (Yip Hang Eddy) Individual Investor
Percentage owned: 25.45% (165.1m shares)
HRT Corporation Pte. Ltd. Corporation
Percentage owned: 9.61% (62.4m shares)
Narulla (Jaspal Singh) Individual Investor
Percentage owned: 6.99% (45.3m shares)
Tang (Choy Leng Jane) Individual Investor
Percentage owned: 2.69% (17.5m shares)
Yeoh (Wee Liat) Individual Investor
Percentage owned: 2.11% (13.7m shares)
Similar to 42C
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.